• Consensus Rating: Buy
  • Consensus Price Target: $14.80
  • Forecasted Upside: 108.74 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.09
▼ -0.53 (-6.96%)

This chart shows the closing price for EOLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evolus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EOLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EOLS

Analyst Price Target is $14.80
▲ +108.74% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Evolus in the last 3 months. The average price target is $14.80, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 108.74% upside from the last price of $7.09.

This chart shows the closing price for EOLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Evolus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2022HC WainwrightReiterated RatingBuyLow
6/23/2022Needham & Company LLCInitiated CoverageBuy$18.00Low
5/12/2022BarclaysUpgradeUnderweight ➝ Equal Weight$8.00 ➝ $10.00High
4/28/2022BarclaysBoost Target$7.00 ➝ $8.00Medium
3/4/2022Cantor FitzgeraldReiterated RatingOverweight$20.00High
3/4/2022HC WainwrightReiterated RatingBuy$15.00High
1/20/2022Truist FinancialUpgradeHold ➝ Buy$11.00Medium
11/12/2021SVB LeerinkReiterated RatingBuy$18.00Low
11/3/2021HC WainwrightLower TargetBuy$22.00 ➝ $15.00High
10/18/2021SVB LeerinkReiterated RatingOutperformMedium
8/8/2021SVB LeerinkReiterated RatingBuy$18.00Medium
5/19/2021SVB LeerinkReiterated RatingBuy$18.00Low
5/13/2021BarclaysLower TargetUnderweight$8.00 ➝ $7.00High
5/6/2021MizuhoUpgradeNeutral ➝ Buy$15.00High
4/8/2021HC WainwrightReiterated RatingBuy$20.00 ➝ $22.00Low
3/30/2021MizuhoBoost TargetNeutral$9.00 ➝ $15.00Low
3/24/2021HC WainwrightBoost TargetBuy$18.00 ➝ $20.00Medium
2/24/2021Truist FinancialDowngradeBuy ➝ Hold$12.00Low
2/22/2021BarclaysBoost TargetPositive ➝ Underweight$4.00 ➝ $8.00Medium
2/22/2021Cantor FitzgeraldBoost TargetOverweight$11.00 ➝ $20.00Medium
2/22/2021MizuhoBoost TargetNeutral$5.00 ➝ $9.00Medium
2/22/2021HC WainwrightBoost TargetBuy$6.00 ➝ $18.00Medium
2/19/2021Stifel NicolausBoost TargetBuy$11.00 ➝ $25.00High
12/17/2020HC WainwrightLower TargetBuy$8.00 ➝ $6.00High
9/22/2020MizuhoReiterated RatingHold$5.00Medium
8/11/2020HC WainwrightBoost TargetBuy$7.00 ➝ $8.00High
7/7/2020SunTrust BanksLower TargetBuy$12.00 ➝ $6.00High
7/7/2020MizuhoDowngradeBuy ➝ Neutral$8.00 ➝ $3.00High
7/7/2020HC WainwrightLower TargetBuy$15.00 ➝ $7.00High
5/13/2020BarclaysLower TargetUnderweight$9.00 ➝ $4.00High
5/12/2020HC WainwrightReiterated RatingBuy$15.00Low
5/12/2020SunTrust BanksLower TargetBuy$18.00 ➝ $12.00High
5/12/2020MizuhoLower TargetBuy$10.00 ➝ $8.00High
4/30/2020Wells Fargo & CompanyLower TargetEqual Weight$10.00 ➝ $5.00Medium
4/20/2020HC WainwrightReiterated RatingBuy$16.00High
4/17/2020MizuhoLower TargetBuy$12.00 ➝ $10.00Medium
4/16/2020Stifel NicolausLower TargetBuy$30.00 ➝ $25.00Low
4/3/2020SVB LeerinkLower TargetOutperform$25.00 ➝ $15.00Medium
3/27/2020HC WainwrightLower TargetBuy$31.00 ➝ $16.00High
2/27/2020BarclaysReiterated RatingSell$9.00High
2/26/2020HC WainwrightLower TargetBuy$34.00 ➝ $31.00Low
2/25/2020MizuhoReiterated RatingBuy$20.00Low
2/20/2020HC WainwrightLower TargetBuy$37.00 ➝ $34.00Medium
2/5/2020MizuhoInitiated CoverageBuy$20.00High
1/21/2020MizuhoReiterated RatingBuy$30.00Low
11/26/2019SVB LeerinkInitiated CoverageOutperform$25.00Medium
11/5/2019HC WainwrightReiterated RatingBuyLow
9/5/2019MizuhoReiterated RatingBuy$30.00Low
8/13/2019JMP SecuritiesLower TargetMarket Outperform$35.00 ➝ $30.00High
7/31/2019Stifel NicolausSet TargetBuy$33.00Low
6/28/2019Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$16.00Medium
6/11/2019BarclaysInitiated CoverageUnderweight ➝ Underweight$13.00High
5/20/2019MizuhoSet TargetBuy$31.00Medium
4/30/2019Cantor FitzgeraldReiterated RatingBuy$35.00High
4/4/2019HC WainwrightReiterated RatingBuy$37.00Low
3/20/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$30.00High
3/19/2019Cantor FitzgeraldReiterated RatingOverweightHigh
3/19/2019MizuhoBoost TargetBuy ➝ Buy$25.00 ➝ $29.00High
2/14/2019HC WainwrightInitiated CoverageBuy$37.00High
1/28/2019Stifel NicolausInitiated CoverageBuy$27.00High
9/27/2018Cantor FitzgeraldSet TargetBuy$35.00Low
9/17/2018Cantor FitzgeraldReiterated RatingBuy$35.00Low
8/29/2018Cantor FitzgeraldSet TargetBuy$35.00High
8/17/2018Cantor FitzgeraldSet TargetBuy$35.00Low
8/6/2018SunTrust BanksReiterated RatingBuy$27.00High
8/2/2018JMP SecuritiesReiterated RatingOutperform$35.00High
8/2/2018Cantor FitzgeraldSet TargetBuy$35.00Medium
7/23/2018Cantor FitzgeraldSet TargetBuy$35.00Medium
6/13/2018Cantor FitzgeraldSet TargetOverweight ➝ Buy$25.00 ➝ $35.00Medium
6/11/2018MizuhoBoost TargetBuy ➝ Buy$16.00 ➝ $33.00High
6/7/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
5/29/2018JMP SecuritiesBoost TargetOutperform$22.00 ➝ $30.00High
5/16/2018MizuhoReiterated RatingBuyHigh
4/25/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
4/19/2018MizuhoReiterated RatingBuy$21.00High
3/5/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$20.00Medium
3/5/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00 ➝ $24.00Medium
3/5/2018MizuhoInitiated CoverageBuy ➝ Buy$21.00Medium
3/5/2018Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/1/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/30/2022
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

Evolus logo
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Read More

Today's Range

Now: $7.09
Low: $7.03
High: $7.66

50 Day Range

MA: $8.12
Low: $7.07
High: $9.53

52 Week Range

Now: $7.09
Low: $5.06
High: $14.34

Volume

293,319 shs

Average Volume

485,037 shs

Market Capitalization

$398.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Evolus?

The following Wall Street sell-side analysts have issued research reports on Evolus in the last year: Barclays PLC, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, and Truist Financial Co..
View the latest analyst ratings for EOLS.

What is the current price target for Evolus?

5 Wall Street analysts have set twelve-month price targets for Evolus in the last year. Their average twelve-month price target is $14.80, suggesting a possible upside of 108.7%. Cantor Fitzgerald has the highest price target set, predicting EOLS will reach $20.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $10.00 for Evolus in the next year.
View the latest price targets for EOLS.

What is the current consensus analyst rating for Evolus?

Evolus currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EOLS will outperform the market and that investors should add to their positions of Evolus.
View the latest ratings for EOLS.

What other companies compete with Evolus?

How do I contact Evolus' investor relations team?

Evolus' physical mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company's listed phone number is (949) 284-4555 and its investor relations email address is [email protected] The official website for Evolus is www.evolus.com. Learn More about contacing Evolus investor relations.